Cabaletta Bio, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Fair Value Measurements (Tables)

Fair Value Measurements (Tables)

3 Months Ended

Mar. 31, 2022

Financial Assets Measured at Fair Value on Recurring Basis

The following tables present financial information about the Company’s financial assets measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values:

	March 31, 2022
	Total		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Financial assets
Cash and Cash equivalents:
Money market funds	$	59,553	$	59,553	$	—	$	—
Short-term investments:
U.S. Government securities		49,660		—		49,660		—
Total	$	109,213	$	59,553	$	49,660	$	—

	December 31, 2021
	Total		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Financial assets
Cash and Cash equivalents:
Money market funds	$	122,222	$	122,222	$	—	$	—
Total	$	122,222	$	122,222	$	—	$	—

Schedule of Debt Securities Classified as Available-for-Sale Investments

For debt securities classified as available-for-sale investments, the Company records unrealized gains or losses resulting from changes in fair value between measurement dates as a component of other comprehensive income. The Company did not hold any available-for-sale securities as of December 31, 2021.

	March 31, 2022
	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Fair value
Financial assets
Money market funds
Included in cash and cash equivalents	$	59,553	$	—	$	—		$	59,553
U.S. Government securities - due in one year or less
Included in short-term investments		49,812				(152	)		49,660
Total	$	109,365	$	—	$	(152	)	$	109,213